A compact Cas12f nuclease shows high editing efficiency in human cells, with structural insights enabling an engineered variant potentially suited for future AAV‑compatible delivery.
The draft guidance supports the agency’s new pathway designed to speed up the development of custom gene therapies.
NIH-funded UT team and colleagues from Metagenomi Thereapeutics discovered highly efficient enzyme could enable targeted gene editing within the human body.
The rapid evolution of CRISPR/Cas genome editing has redefined the possibilities of cellular and gene therapy, enabling ...
The CRISPR-Cas gene-editing system has long been the focus of research as a promising tool in genome editing. However, the ...
The US Food and Drug Administration (FDA) has released draft guidance on how sponsors can utilize next-generation sequencing ...
The US Food and Drug Administration (FDA) today issued a draft guidance for sponsors seeking approval of human gene therapy ...
Key market opportunities include advancements in research, medicine, diagnostics, and biotechnology through CRISPR. There is potential for innovative solutions and ethical exploration in gene editing, ...
The genome has thousands of genes that code for proteins, which help carry out many of the cell's important functions. But ...
Scientists have gained tremendous control over the genome with CRISPR editing systems, that use a guide RNA molecule to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results